GlioCART
Fighting Glioblastoma at its Core
Glioblastoma(GBM)
Next-generation CAR-T therapy for GBM
GlioCART is a University of Basel spin-off focused on translating a dual-action CAR-T therapy for GBM into clinical application
Combining tumor targeting with immune microenvironment reprogramming
Our mission is to achieve durable clinical benefit for patients with glioblastoma
Our Technology
Dual-mechanism CAR-T cells targeting tumor antigens and the myeloid compartment
Mechanism 1: Direct Killing of EGFRvIII+ Tumor cells
Mechanism 2: Local secretion of a CD47-blocking molecule to reprogram tumor-associated macrophages
Designed to overcome immune suppression and tumor heterogeneity in GBM
Development Pathway
Preclinical proof-of-concept established and published in
(for publication, click logo above)
Clinical trial preparation in progress
Intellectual Property
PCT nationalisation phase entered in major jurisdictions
© GlioCART GmbH – All rights reserved
This website is intended for informational purposes only and does not constitute medical advice.